Gilead director granted RSUs and options
Gilead Sciences director Jacqueline K. Barton received equity compensation on April 30, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Gilead Sciences director Jacqueline K. Barton received equity compensation on April 30, 2026. She was granted 1,146 restricted stock units that vested immediately, each representing one share of common stock, bringing her direct holdings to 27,202 shares. She also received a non-qualified stock option for 4,884 shares at an exercise price of $130.84 per share, with all option shares vesting immediately and expiring on April 30, 2036.
Insider Trade Summary
Grant/Award: 6,030 shares
Grant/Award
2 txns
Insider
BARTON JACQUELINE K
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Non-qualified Stock Option (Right to Buy) | 4,884 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 1,146 | $0.00 | $0.00 |
Holdings After Transaction:
Non-qualified Stock Option (Right to Buy) — 4,884 contracts (Direct);
Common Stock — 27,202 shares (Direct)
Footnotes (2)
- F1. Represents 1,146 restricted stock units ("RSUs") granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. The RSUs vested immediately upon the grant date of April 30, 2026.
- F2. 100% of the shares subject to the stock option vested immediately upon the grant date of April 30, 2026.
Key Figures
RSUs granted: 1,146 RSUs
Shares held after grant: 27,202 shares
Stock options granted: 4,884 options
+2 more
5 metrics
RSUs granted
1,146 RSUs
Granted April 30, 2026; each equals one common share
Shares held after grant
27,202 shares
Common stock directly owned after RSU vesting
Stock options granted
4,884 options
Non-qualified stock option, right to buy common shares
Option exercise price
$130.84 per share
Conversion/exercise price for new options
Option expiration
April 30, 2036
Expiration date of non-qualified stock option
Key Terms
restricted stock units, RSUs, Non-qualified Stock Option, Equity Incentive Plan, +1 more
5 terms
restricted stock units financial
"Represents 1,146 restricted stock units ("RSUs") granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
RSUs financial
"Each RSU represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock."
RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.
Non-qualified Stock Option financial
"Non-qualified Stock Option (Right to Buy)"
A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.
Equity Incentive Plan financial
"granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan."
An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.
contingent right financial
"Each RSU represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock."
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Gilead (GILD) director Jacqueline K. Barton acquire in this Form 4 filing?
Jacqueline K. Barton received 1,146 restricted stock units and a non-qualified stock option for 4,884 shares of Gilead common stock. Both awards were granted as equity compensation on April 30, 2026, and vested immediately on the grant date.
What are the key terms of Jacqueline K. Barton’s new Gilead (GILD) stock options?
Barton received a non-qualified stock option for 4,884 shares of Gilead common stock with an exercise price of $130.84 per share. All option shares vested immediately and the option expires on April 30, 2036, according to the Form 4 footnotes.
Under which plan were Jacqueline K. Barton’s Gilead (GILD) equity awards granted?
The 1,146 RSUs reported in the Form 4 were granted under the Gilead Sciences, Inc. 2022 Equity Incentive Plan. The filing notes that each RSU equals one share of common stock and that the units vested in full on the April 30, 2026 grant date.
AI-generated analysis. How Rhea-AI works. Not financial advice.
